First City Capital Management Inc. Takes Position in Gilead Sciences, Inc. (NASDAQ:GILD)

First City Capital Management Inc. bought a new stake in shares of Gilead Sciences, Inc. (NASDAQ:GILD) in the second quarter, according to its most recent Form 13F filing with the SEC. The fund bought 10,827 shares of the biopharmaceutical company’s stock, valued at approximately $766,000.

A number of other institutional investors have also recently bought and sold shares of GILD. Penserra Capital Management LLC lifted its stake in shares of Gilead Sciences by 9.5% in the 1st quarter. Penserra Capital Management LLC now owns 1,656 shares of the biopharmaceutical company’s stock worth $112,000 after acquiring an additional 144 shares during the period. American Beacon Advisors Inc. acquired a new stake in shares of Gilead Sciences in the 1st quarter worth approximately $143,000. Harel Insurance Investments & Financial Services Ltd. lifted its stake in shares of Gilead Sciences by 29.3% in the 2nd quarter. Harel Insurance Investments & Financial Services Ltd. now owns 2,120 shares of the biopharmaceutical company’s stock worth $150,000 after acquiring an additional 480 shares during the period. Capstone Investment Advisors Netherlands B.V. acquired a new stake in shares of Gilead Sciences in the 2nd quarter worth approximately $172,000. Finally, Sterling Investment Advisors Ltd. acquired a new stake in shares of Gilead Sciences in the 2nd quarter worth approximately $184,000. 75.94% of the stock is owned by hedge funds and other institutional investors.

A number of analysts have recently weighed in on GILD shares. TheStreet raised shares of Gilead Sciences from a “c+” rating to a “b-” rating in a research note on Thursday, September 7th. Berenberg Bank reaffirmed a “buy” rating and issued a $96.00 price target (up from $86.00) on shares of Gilead Sciences in a research note on Wednesday, September 6th. Vetr raised shares of Gilead Sciences from a “hold” rating to a “buy” rating and set a $89.27 target price for the company in a research note on Wednesday, September 6th. Mizuho reissued a “buy” rating on shares of Gilead Sciences in a research note on Friday, September 29th. Finally, ValuEngine lowered shares of Gilead Sciences from a “strong-buy” rating to a “buy” rating in a research note on Wednesday, September 13th. One equities research analyst has rated the stock with a sell rating, thirteen have assigned a hold rating, seventeen have assigned a buy rating and one has issued a strong buy rating to the company. The company has an average rating of “Buy” and an average price target of $85.03.

Gilead Sciences, Inc. (NASDAQ GILD) traded down $0.84 during mid-day trading on Friday, hitting $71.64. 7,346,379 shares of the stock were exchanged, compared to its average volume of 7,466,062. Gilead Sciences, Inc. has a twelve month low of $63.76 and a twelve month high of $86.27. The company has a debt-to-equity ratio of 1.10, a current ratio of 3.68 and a quick ratio of 3.56. The firm has a market capitalization of $94,678.38, a price-to-earnings ratio of 8.16, a P/E/G ratio of -1.21 and a beta of 1.13.

Gilead Sciences (NASDAQ:GILD) last released its quarterly earnings results on Thursday, October 26th. The biopharmaceutical company reported $2.27 earnings per share (EPS) for the quarter, beating the Zacks’ consensus estimate of $2.13 by $0.14. Gilead Sciences had a net margin of 42.22% and a return on equity of 57.15%. The business had revenue of $6.51 billion for the quarter, compared to analyst estimates of $6.40 billion. During the same quarter in the previous year, the business earned $2.75 earnings per share. The firm’s revenue was down 13.2% compared to the same quarter last year. equities research analysts predict that Gilead Sciences, Inc. will post 8.53 EPS for the current fiscal year.

The company also recently declared a quarterly dividend, which was paid on Thursday, December 28th. Stockholders of record on Friday, December 15th were issued a dividend of $0.52 per share. The ex-dividend date of this dividend was Thursday, December 14th. This represents a $2.08 dividend on an annualized basis and a dividend yield of 2.90%. Gilead Sciences’s dividend payout ratio is currently 23.69%.

In other Gilead Sciences news, insider John C. Martin sold 73,333 shares of the company’s stock in a transaction that occurred on Monday, October 2nd. The shares were sold at an average price of $82.56, for a total value of $6,054,372.48. The transaction was disclosed in a document filed with the SEC, which is available at this link. Also, insider John F. Milligan sold 220,000 shares of the company’s stock in a transaction that occurred on Monday, November 13th. The shares were sold at an average price of $72.88, for a total transaction of $16,033,600.00. The disclosure for this sale can be found here. Insiders have sold 494,999 shares of company stock worth $37,404,139 in the last 90 days. 1.30% of the stock is owned by company insiders.

ILLEGAL ACTIVITY NOTICE: “First City Capital Management Inc. Takes Position in Gilead Sciences, Inc. (NASDAQ:GILD)” was published by Week Herald and is the property of of Week Herald. If you are accessing this article on another website, it was illegally copied and republished in violation of United States and international trademark and copyright law. The correct version of this article can be accessed at https://weekherald.com/2017/12/30/first-city-capital-management-inc-purchases-shares-of-10827-gilead-sciences-inc-gild.html.

Gilead Sciences Profile

Gilead Sciences, Inc is a research-based biopharmaceutical company that discovers, develops and commercializes medicines in areas of unmet medical need. The Company’s portfolio of products and pipeline of investigational drugs includes treatments for Human Immunodeficiency Virus/Acquired Immune Deficiency Syndrome (HIV/AIDS), liver diseases, cancer, inflammatory and respiratory diseases and cardiovascular conditions.

Institutional Ownership by Quarter for Gilead Sciences (NASDAQ:GILD)

Receive News & Ratings for Gilead Sciences Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Gilead Sciences and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply